Liu et al. demonstrated that Trastuzumab, the monoclonal antibody against HER2, increased the sensitivity of HER2-amplified human GC cells to OXA and cisplatin by affecting the expression of telomere-associated proteins (20). Here, ERBB2 is linked to gastric cancer.